We assessed the clinical trajectory of patients with TP53‐aberrant MDS versus AML based on key management decision points including decisions about curative versus palliative intent therapy and candidacy for HCT (Figure 6A). This evidence concerns the gene TP53 and myelodysplastic syndrome.